194 related articles for article (PubMed ID: 30842173)
21. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
22. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients.
Suer E; Hamidi N; Akpinar C; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
Urol J; 2019 Oct; 16(5):453-457. PubMed ID: 30636274
[TBL] [Abstract][Full Text] [Related]
24. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
25. Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer.
Kaliks RA; Santi P; Cardoso AP; Giglio AD
Int Braz J Urol; 2010; 36(3):300-7. PubMed ID: 20602822
[TBL] [Abstract][Full Text] [Related]
26. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
Smith MR; Cook R; Lee KA; Nelson JB
Cancer; 2011 May; 117(10):2077-85. PubMed ID: 21523719
[TBL] [Abstract][Full Text] [Related]
27. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
28. Selective lymph node dissection for castration-resistant prostate cancer.
Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
[TBL] [Abstract][Full Text] [Related]
29. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
[TBL] [Abstract][Full Text] [Related]
30. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera PA; Shetty AC; Hakansson A; Van der Eecken K; Song Y; Liu Y; Chang J; Fonteyne V; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Rana Z; Hodges T; Hamid A; Roberts N; Song DY; Pienta K; Ross AE; Feng F; Joniau S; Spratt D; Gillessen S; Attard G; James ND; Lotan T; Davicioni E; Sweeney C; Tran PT; Deek MP; Ost P
Ann Oncol; 2023 Jul; 34(7):605-614. PubMed ID: 37164128
[TBL] [Abstract][Full Text] [Related]
31. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
33. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Shimodaira K; Nakashima J; Nakagami Y; Hirasawa Y; Hashimoto T; Satake N; Gondo T; Namiki K; Ohori M; Ohno Y
Urol J; 2020 Jan; 17(1):42-49. PubMed ID: 30882158
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
37. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
38. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Regis L; Planas J; Carles J; Maldonado X; Comas I; Ferrer R; Morote J
Prostate; 2017 Jan; 77(1):114-120. PubMed ID: 27800640
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.
Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687
[TBL] [Abstract][Full Text] [Related]
40. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
